Evidence map›Paper›PMID 39207521›Full record

ArticleJournal of neurology2024

Pharmacotherapy of motor symptoms in early and mid-stage Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.

Matthias Höllerhage, Jos Becktepe, Joseph Classen, Günther Deuschl, Georg Ebersbach, Franziska Hopfner, Paul Lingor, Matthias Löhle, Sylvia Maaß, Monika Pötter-Nerger and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Treatment Options for Motor Fluctuations in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Matthias HöllerhageDepartment of Neurology, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0002-5333-0121
Jos BecktepeDepartment of Neurology, Christian-Albrechts-University, Kiel, Germany.
Joseph ClassenDepartment of Neurology, Leipzig University Medical Center, Leipzig, Germany.
Günther DeuschlDepartment of Neurology, Christian-Albrechts-University, Kiel, Germany.
Georg EbersbachMovement Disorders Hospital, Beelitz-Heilstätten, Germany.
Franziska HopfnerDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Marchioninistr. 15, 81377, Munich, Germany.
Paul LingorSchool of Medicine and Health, Department of Neurology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
Matthias LöhleDepartment of Neurology, University of Rostock, 18051, Rostock, Germany.
Sylvia MaaßGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Monika Pötter-NergerDepartment of Neurology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Per OdinDivision of Neurology, Lund University, Lund, Sweden.
Dirk WoitallaDepartment of Neurology, St. Josef-Hospital, Katholische Kliniken Ruhrhalbinsel, Contilia Gruppe, Essen, Germany.
German Parkinson’s Guidelines Group
Claudia TrenkwalderParacelsus-Elena-Klinik, Kassel, Germany.
Günter U HöglingerDepartment of Neurology with Friedrich Baur Institute, LMU University Hospital, Ludwig-Maximilians-Universität (LMU) München, Marchioninistr. 15, 81377, Munich, Germany. Guenter.Hoeglinger@med.uni-muenchen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThere are multiple pharmacological treatment options for motor symptoms of Parkinson's disease (PD). These comprise multiple drug classes which are approved for the condition, including levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, NMDA-receptor antagonists, anticholinergics, and others. Some of the drugs are approved for monotherapy and combination therapy while others are only approved as adjunctive therapy to levodopa. Furthermore, treatment for special treatment situations, e.g., rescue medication for off-phases, for tremor, treatment during pregnancy and breast feeding is discussed and recommendations are given with further details.

methodsThe recommendations were based on systematic literature reviews, drafted by expert teams, consented in online polls followed by online consensus meetings of the whole German Parkinson's Guideline Group, and publicly released in November 2023.

resultsIn the new S2k (i.e., consensus-based) guidelines, the pharmacotherapy of the motor symptoms of PD is discussed in five chapters. These comprise "Parkinson medication", "Initial monotherapy", "Early combination therapy", "Fluctuations and dyskinesia", and "Parkinsonian tremor". Furthermore, there is a chapter for special treatment situations, including perioperative management, freezing of gait, and pregnancy and breastfeeding.

conclusionThe recommendations for the pharmacotherapy of motor symptoms of PD have been updated. Newly available drugs have been added, while other drugs (e.g., ergoline dopamine agonists, anticholinergics, budipine) have been removed from the recommendations.

Indexed as

Antiparkinson AgentsNeurologyParkinson DiseaseGermanyHumansPractice Guidelines as TopicSocieties, MedicalSystematic Reviews as TopicAntiparkinson AgentsGuidelinesParkinson's diseasePharmacotherapy

Identifiers

PMID39207521
PMCPMC11561004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.